Richter et al., 2023 - Google Patents
Inhibition of muscarinic receptor signaling protects human enteric inhibitory neurons against platin chemotherapy toxicityRichter et al., 2023
View PDF- Document ID
- 6448670501144453968
- Author
- Richter M
- Farahvashi S
- Samuel R
- Majd H
- Chemel A
- Ramirez J
- Majd A
- Scantlen M
- Elder N
- Cesiulis A
- Garcia K
- Joshi T
- Keefe M
- Samiakalantari B
- Turkalj E
- Yu J
- Arab A
- Yin K
- Culbertson B
- Vora B
- Xiong C
- Kattah M
- Irannejad R
- Kroetz D
- Nowakowski T
- Goodarzi H
- Fattahi F
- Publication year
- Publication venue
- BioRxiv
External Links
Snippet
GI toxicity is a common dose-limiting adverse effect of platin chemotherapy treatment. Up to 50% of cancer survivors continue to experience symptoms of chronic constipation or diarrhea induced by their chemotherapy for many years after their treatment. This drug …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fortress et al. | Canonical Wnt signaling is necessary for object recognition memory consolidation | |
Wang et al. | Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells | |
Luo et al. | Microarray analysis of selected genes in neural stem and progenitor cells | |
McEvoy et al. | Coexpression of normally incompatible developmental pathways in retinoblastoma genesis | |
Jarazo et al. | Parkinson's disease phenotypes in patient neuronal cultures and brain organoids improved by 2‐Hydroxypropyl‐β‐Cyclodextrin treatment | |
Pacheco-López et al. | Neural substrates for behaviorally conditioned immunosuppression in the rat | |
Hwang et al. | Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation | |
Huang et al. | Neuroprotective effects of reactive oxygen species mediated by BDNF-independent activation of TrkB | |
Upadhyay et al. | Dysregulation of multiple signaling neurodevelopmental pathways during embryogenesis: a possible cause of autism spectrum disorder | |
Wegscheid et al. | Patient-derived iPSC-cerebral organoid modeling of the 17q11. 2 microdeletion syndrome establishes CRLF3 as a critical regulator of neurogenesis | |
Shin et al. | Sertindole, a potent antagonist at dopamine D2 receptors, induces autophagy by increasing reactive oxygen species in SH-SY5Y neuroblastoma cells | |
US20150025017A1 (en) | Compositions and methods for treating cancer | |
Wu et al. | Impairments of spatial learning and memory following intrahippocampal injection in rats of 3-mercaptopropionic acid-modified CdTe quantum dots and molecular mechanisms | |
Somerville et al. | Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response | |
Lago et al. | Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo | |
Richter et al. | Inhibition of muscarinic receptor signaling protects human enteric inhibitory neurons against platin chemotherapy toxicity | |
Wen et al. | Low concentration trifluoperazine promotes proliferation and reduces calcium-dependent apoptosis in glioma cells | |
Ivanova et al. | Targeting FER kinase inhibits melanoma growth and metastasis | |
Xing et al. | Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway | |
Liu et al. | Identification of PIK3CG as a hub in septic myocardial injury using network pharmacology and weighted gene co‐expression network analysis | |
de Bartolomeis et al. | Canonical and non-canonical antipsychotics’ dopamine-related mechanisms of present and next generation molecules: a systematic review on translational highlights for treatment response and treatment-resistant schizophrenia | |
Russell et al. | Exploring the potential of RET kinase inhibition for irritable bowel syndrome: a preclinical investigation in rodent models of colonic hypersensitivity | |
US20220087950A1 (en) | Compounds, targets and pathways for macrophage modulation | |
Feng et al. | A rat study model of depression‐driven chronic prostatitis by modulating the PI3K/Akt/mTOR network | |
Lee et al. | High‐dose compound heat map for 3D‐cultured glioblastoma multiforme cells in a micropillar and microwell chip platform |